CCR5: C-C chemokine receptor type 5
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level.
- Drugs that act on it: 12
- With a US drug page: 1
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Maraviroc | Approved | C-C chemokine receptor type 5 antagonist | Antagonist | Boxed warning |
| Aplaviroc | — | C-C chemokine receptor type 5 antagonist | Antagonist | — |
| AZD5672 | — | C-C chemokine receptor type 5 antagonist | Antagonist | — |
| BMS-813160 | — | C-C chemokine receptor type 5 antagonist | Antagonist | — |
| CCR5MAB004 | — | C-C chemokine receptor type 5 inhibitor | Inhibitor | — |
| Cenicriviroc | — | C-C chemokine receptor type 5 antagonist | Antagonist | — |
| HGS-1025 | — | C-C chemokine receptor type 5 inhibitor | Inhibitor | — |
| INCB-9471 | — | C-C chemokine receptor type 5 antagonist | Antagonist | — |
| Leronlimab | — | C-C chemokine receptor type 5 antagonist | Antagonist | — |
| PF-04634817 | — | C-C chemokine receptor type 5 antagonist | Antagonist | — |
| PF-232798 | — | C-C chemokine receptor type 5 inhibitor | Inhibitor | — |
| Vicriviroc | — | C-C chemokine receptor type 5 antagonist | Antagonist | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- HIV infectious disease
- 0.74
- HIV-1 infection
- 0.63
- COVID-19
- 0.41
- Viral infectious disease
- 0.38
- Type 1 diabetes mellitus
- 0.34
- Erythema nodosum
- 0.34
- Inflammatory bowel disease
- 0.31
- AIDS
- 0.28
- Pneumonia
- 0.26
Drugs and mechanisms are from ChEMBL CHEMBL274 (CC BY-SA 3.0). Gene name, function (UniProt P51681, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets